Page 3 - Fibrosis Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Treatment with Zeposia demonstrated a low annualized relapse rate of 0.103 and more than 70% of patients were relapse-free at four years Safety was consistent with prior findings and the established safety profile of Zeposia in up to 5 years of follow-up Bristol Myers Squibb today announced interim results from the Phase 3 open-label extension trial DAYBREAK, demonstrating the long-term efficacy and safety profile ...

– John Shiver, Ph.D., and Tong-Ming Fu, M.D., Ph.D., Appointed as Chief Strategy Officer and Chief Scientific Officer, Respectively, of IGM Infectious...

Bristol Myers Squibb (NYSE:BMY) today announced that additional data from multiple studies evaluating Zeposia (ozanimod) in ulcerative colitis (UC) were presented at Digestive Disease Week ® (DDW), taking place virtually May 21-23, 2021. These data deepen the understanding of Zeposia and reinforce Bristol Myers Squibb’s commitment to understanding and addressing unmet needs in gastroenterology. Research being shared includes: Safety of Ozanimod in Patients with Moderately to Severely Active Ulcerative Colitis Over Time: Pooled Analysis from Phase 2, Phase 3, and Open-Label Extension...

Bristol Myers Squibb Presents Positive Data from Two Pivotal Phase 3 Psoriasis Studies Demonstrating Superiority of Deucravacitinib Compared to Placebo and Otezla® Significantly more patients treated with deucravacitinib achieved PASI 75 and sPGA 01 compared to patients treated with placebo and Otezla at Week 16, with an increased benefit versus Otezla at Week 24 and maintained through Week 52 Deucravacitinib was well tolerated with a low rate of discontinuation due to adverse events Deucravacitinib is a first-in-class, oral, selective tyrosine kinase 2 inhibitor with a unique … Significa...

Bristol Myers Squibb: EMA Validates Marketing Authorization Application For Zeposia NEW YORK CITY (dpa-AFX) - Bristol Myers Squibb (BMY) said the European Medicines Agency has validated its Marketing Authorization Application for Zeposia for the treatment of adults with moderately to severely active ulcerative colitis. This confirms the submission is complete and begins the EMA's centralized review process. Mary Beth Harler, head of Immunology and Fibrosis Development, Bristol Myers Squibb, said: 'This validation is an important step toward making Zeposia available to eligible patients in the...